The 2017 Hormone Therapy Position Statement of The North American Menopause Society

The North American Menopause Society 2017 Hormone Therapy Position Statement Advisory Panel

Disclosures

The North American Menopause Society (NAMS). 2018;24(7):728-753. 

In This Article

Fda-approved Indications

Vasomotor Symptoms

Hormone therapy has been shown in double-blind RCTs to relieve hot flashes[23] and is approved as first-line therapy for relief of menopause symptoms in appropriate candidates.

Prevention of Bone Loss

Hormone therapy has been shown in double-blind RCTs to prevent bone loss, and in the WHI, to reduce fractures in postmenopausal women.[24,25]

Premature Hypoestrogenism

Hormone therapy is approved for women with hypogonadism, POI, or premature surgical menopause without contraindications, with health benefits for menopause symptoms, prevention of bone loss, cognition and mood issues, and in observational studies, heart disease.[26–31]

Genitourinary Symptoms

Hormone therapy has been shown in RCTs to effectively restore genitourinary tract anatomy, increase superficial vaginal cells, reduce vaginal pH, and treat symptoms of vulvovaginal atrophy (VVA).[32]

Key Point

  • Hormone therapy is approved by FDA for four indications: bothersome VMS; prevention of bone loss; hypoestrogen ism caused by hypogonadism, castration, or POI; and genitourinary symptoms.

Comments

3090D553-9492-4563-8681-AD288FA52ACE

processing....